Stock Movers SoHo and Dayforce Private Talks; Novo and Tonix See Pharma Jump
Aug 18, 2025
Soho House is set to go private, which has driven its shares higher. Dayforce is also in talks for a buyout that could soon be announced. In the pharmaceutical world, Novo Nordisk's weight-loss drug received FDA approval for treating liver disease, boosting its share price. Meanwhile, Tonix Pharmaceuticals saw a surge after getting FDA clearance for its fibromyalgia treatment. These developments highlight the dynamic shifts in the stock market driven by strategic buyouts and regulatory approvals.
AI Snips
Chapters
Transcript
Episode notes
Soho House Goes Private At $9
- Soho House agreed to go private at $9 a share after pressure from investors following a weak IPO performance.
- The deal values the company at about $2.7 billion and involves significant financing from Apollo Global Management.
Dayforce Buyout Talks Boost Shares
- Thoma Bravo is in talks to take Dayforce private, driving a near 29% pre-market surge in the stock.
- Dayforce is down roughly 60% from 2021 highs despite revenue growth and profitability, making it a buyout target.
Wegovy Approval Expands Novo's Market
- Novo Nordisk's Wegovy won FDA approval to treat a serious form of liver disease, extending the drug's market use.
- The approval gives Novo an edge over Eli Lilly and could shift momentum after a tough start to the year.